Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases

B ERAPs (ERAP1 and ERAP2) are emerging therapeutic targets associated with multiple autoimmune diseases. Genomics will assemble the largest available genetic resource to evaluate how…
posteditor
posteditor
Articles: 17424

Other News